Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 8263 | 7.42 |
09:34 ET | 9392 | 7.43 |
09:36 ET | 800 | 7.47 |
09:38 ET | 2346 | 7.45 |
09:39 ET | 348 | 7.46 |
09:41 ET | 200 | 7.45 |
09:43 ET | 300 | 7.45 |
09:45 ET | 1894 | 7.46 |
09:48 ET | 4042 | 7.49 |
09:50 ET | 1991 | 7.495 |
09:52 ET | 1279 | 7.47 |
09:56 ET | 2105 | 7.48 |
09:57 ET | 1200 | 7.45 |
09:59 ET | 200 | 7.46 |
10:01 ET | 852 | 7.455 |
10:03 ET | 100 | 7.46 |
10:06 ET | 300 | 7.45 |
10:08 ET | 700 | 7.44 |
10:10 ET | 3614 | 7.45 |
10:12 ET | 11985 | 7.5 |
10:14 ET | 1318 | 7.51 |
10:15 ET | 2430 | 7.5 |
10:17 ET | 11395 | 7.49 |
10:21 ET | 400 | 7.49 |
10:24 ET | 1588 | 7.51 |
10:28 ET | 500 | 7.52 |
10:32 ET | 1412 | 7.5 |
10:33 ET | 3626 | 7.49 |
10:35 ET | 100 | 7.495 |
10:37 ET | 928 | 7.515 |
10:39 ET | 200 | 7.52 |
10:42 ET | 880 | 7.53 |
10:44 ET | 2435 | 7.53 |
10:46 ET | 500 | 7.55 |
10:48 ET | 2038 | 7.555 |
10:50 ET | 200 | 7.555 |
10:51 ET | 612 | 7.54 |
10:53 ET | 700 | 7.53 |
10:55 ET | 608 | 7.53 |
10:57 ET | 600 | 7.5 |
11:00 ET | 20147 | 7.56 |
11:02 ET | 300 | 7.57 |
11:04 ET | 100 | 7.56 |
11:06 ET | 1925 | 7.58 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 997.5M | -2.1x | --- |
Prothena Corporation PLC | 1.1B | -20.2x | --- |
Zymeworks Inc | 886.0M | -8.2x | --- |
WAVE Life Sciences Ltd | 1.0B | -14.4x | --- |
Arcutis Biotherapeutics Inc | 1.1B | -4.2x | --- |
Silence Therapeutics PLC | 813.3M | -14.0x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $997.5M |
---|---|
Revenue (TTM) | $78.9M |
Shares Outstanding | 136.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-3.58 |
Book Value | $11.80 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 12.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -715.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.